Chinese biotech shares surge as Big Pharma looks to license cancer treatments

Sector returns are over 60% this year, with investors impressed by rapid pace of innovation

China is innovating at substantially lower costs than its western counterparts, as it benefits from lower salaries and manufacturing costs, a deep pool of researchers and cheaper trials © Bloomberg